Oaktree Acquisition Corp III Life Sciences(OACC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | - | P/E | 39.12 | EPS (ttm) | 0.27 | Insider Own | 19.52% | Shs Outstand | 19.8M | Perf Week | -0.46% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 19.8M | Perf Month | -0.09% |
| Enterprise Value | 0.26B | PEG | - | EPS next Q | - | Inst Own | 79.54% | Short Float | 0.01% | Perf Quarter | 0.84% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.02 | Perf Half Y | 1.13% |
| Sales | 0.00B | P/B | 1.34 | EPS next 5Y | - | ROA | 3.33% | Short Interest | 0.00M | Perf YTD | 1.61% |
| Book/sh | 8.05 | P/C | 223.95 | EPS past 3/5Y | - | ROE | 3.47% | 52W High | -1.15% ($10.88) | Perf Year | 2.48% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | 3.41% | 52W Low | 2.97% ($10.44) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39% | Gross Margin | - | Volatility(W/M) | 0.2% 0.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.73 | EPS Q/Q | -14.3% | Profit Margin | - | RSI (14) | 50.42 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.73 | Sales Q/Q | - | SMA20 | -0.12% ($10.76) | Beta | -0.01 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 0.37% ($10.71) | Rel Volume | 0 | Prev Close | $10.77 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 1.4% ($10.6) | Avg Volume(3M) | 0.05M | Price | $10.75 |
| IPO | 2024/12/16 | Option/Short | No/Yes | Trades | 10 | Volume | 45 | Change | -0.14% |
Company
OACC is a Financial sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A special purpose acquisition company (SPAC) seeking a merger target in the life sciences sector. Global alternative investment manager Oaktree is participating as sponsor, exploring biopharmaceutical, medical device, diagnostics, and specialty healthcare services companies as potential merger targets. The company has no operating business and deposits the funds raised through its IPO into a trust account, where they are held until the merger is completed or the company is liquidated.
Over the past 1 year, roughly in the middle
1% below its 1-year high.
OACC earns at a steady pace
Tap to view numbers
The price looks about right
Trading at 39.1 times earnings.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 79.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SPAQ 0.05%It ranks #4 in the industry
Based on market cap of $264M.
OACC $264M PER 39.1
LION $3B PER -
BBCQ $2B PER -
CCXI $686M PER -
FAQ
What kind of company is OACC?
OACC belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of OACC?
The market cap of OACC is approximately $264M, ranking 3,872 within its sector.
What is the P/E ratio of OACC?
OACC has a P/E ratio of approximately 39.1x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for OACC?
OACC has recorded a 52-week high of $10.88 and a low of $10.44.
